Meeting Notes Therapeutic Products Directorate (TPD) Advisory Committee on Management
(ACM) May 8-9, 2002
TPD Boardroom
Holland Cross, Tower B, 1600 Scott Street
Ottawa, Ontario
Attending
Jim Blackburn, Chair
Luis Barreto (Day 1)
Andrea Baumann (Day 1)
Bernadette M. Connaughton
Ruby Grymonpre
Stuart MacLeod
John Parks
David Skinner
Beverley Townsend (Day 1)
Pamela Zabel
Regrets:
John Blatherwick
Mitchell Levine
Brenda Nunns Shoemaker
Jack Rosentreter
Michael G. Tierney
Jacques Turgeon
David Windross
Presenters
Robert Peterson, Co-Chair, Director General (DG) TPD
Hélène Bélanger, Bureau of Operational Services
(BOS)
Andy Butterfield, BOS
Pauline Gaudry, BOS
Sultan Ghani, Bureau of Pharmaceutical Sciences
Brian Gillespie, Senior Medical Advisor Bureau (SMAB)
Abdullah Hassan, Bureau of Gastro-Enterology, Infection and Viral Diseases
Micheline Ho, SMAB
Pat Huston, SMAB
Naheed Israeli, Policy Bureau (PB)
Robert Leitch, Marketed Health Products Directorate (MHPD)
Karen Proud, Office of Regulatory and International Affairs
Paul Roufail, Bureau of Metabolism, Oncology and Reproductive Sciences
Roland Rotter, Medical Devices Bureau
Philip Waddington, DG Natural Health Products Directorate
Mike Ward, PB
Brigitte Zirger, Bureau of Cardiology, Allergy and Neurological Sciences
Observers
Lynn Bernard, Associate DG TPD
Roger Farley, DG Office of Consumer and Public Involvement
Trish Larwill, BOS
Louis Boulay, Veterinary Drugs Directorate
David Lee, Office of Patented Medicines and Liaison
Supriya Sharma, MHPD
Barbel Traynor, BOS
Secrétariat
Susan Tessier, PB
Denise Quesnel, PB
Chantal Tremblay, PB
DAY 1 - May 8, 2002
1. Opening Remarks
Dr. Blackburn welcomed all. A roundtable of introductions
followed.
Bernadette M. Connaughton, President and General Manager
of Bristol-Myers Squibb Canada was welcomed as a new member. Three additional
new members, who had sent their regrets and will attend the next meeting,
were announced. They are:
Dr. Michael G. Tierney, Pharmacy Department, Ottawa Hospital,
Dr. Jacques Turgeon, Dean, Faculty of Pharmacy, University of Montréal
and
Mr. David T. Windross, VP, Government and Professional Affairs, Novopharm
Dr. Peterson encouraged ACM members to provide their feedback
and advice into the organizational changes that were taking place at
TPD, in part as a result of Health Canada realignment. He announced
that Ian Green, the Deputy Minister of Health, would be guest speaker
at dinner that evening.
2. Review of the December 5 & 6, 2001 Meeting Notes and
Agenda
The previous meeting notes were accepted as distributed.
David Skinner wished to add an agenda item: update on
the future of ProxTox. This pilot is a project of the Centre for Disease
Surveillance in the Population and Public Health Branch and, as such,
not within the mandate of TPD. D. Skinner was directed to the appropriate
individuals. The agenda was accepted as distributed.
3. Management Issues
3.1 TPD Reorganization
Dr. Peterson reported that TPD has undergone significant
restructuring. This was done after careful consideration of several
models and staff and focus groups' statement of operational needs.
These changes have also been reviewed at the Branch and Departmental
levels and were announced formally on April 2, 2002. The Bureau of Pharmaceutical
Assessment has been divided into five functional units which respond
to workload distribution, performance measures, quality systems, backlog
and screening program requirements. These processes used to be discrete
but are now integrated into the review itself. The new Senior Medical
Advisor Bureau has brought together a number of stand alone responsibilities,
including the Clinical Trials and Special Access Programme, product
information, non-prescription drug evaluation, risk management, quality
assurance and level 1 appeals. Patents is a growing issue within Canada
and the US; a new Office of Patented Medicines and Liaison reports directly
to the DG. The ACM suggested that work with the Patented Medicines Review
Board would be useful and reduce duplication of efforts.
a) Senior Medical Advisor Bureau (SMAB)
Dr. Brian Gillespie gave an overview of this new unit.
He described the Clinical Trials and Special Access Programme (SAP)
and their experience under the modernized regulatory framework which
was introduced in Sept. 2001. The SAP is a single window which administers
blood products and biologics as well as drugs and has responsibility
for emergency response regarding supply of these products. Also profiled
were the Nonprescription Drug Evaluation Unit, Product Information Division
and the Risk Management/Postmarket Liaison Division. It was clarified
that clinical trial inspections are done by the Health Products and
Foods Branch (HPFB) Inspectorate, supported by TPD who does the review.
TPD handles, on average, 4 switches/year and it can take significant
time to resolve the clinical issues in these cases. Most applications
are for ingredient, rather than class, switches. The difficulties in
advising and communicating with health care professionals and consumers
was acknowledged; the TPD is committed to working with MHPD to minimize
these.
b) Bureau of Metabolism, Oncology and Reproductive Sciences
(BMORS)
Dr. Paul Roufail described the Metabolic and Musculoskeletal
Drugs, Anti-neoplastic Drugs and Reproduction and Urology Divisions
within this group. The benefits expected from the new organization is
equitable workload, close relationships between divisions, flexibility
in distributing workload among divisions and improved review performance.
As well, it is anticipated that there will be more interaction between
the managers and reviewers and industry resulting from the smaller divisions.
The challenges will be efficiency of reviews and performance targets,
balances between internal resources and external experts, priority review
and Notice of Compliance with Conditions (NOC-C) issues. The ACM felt
that using pre-review panels paid for by industry to look at issues
and give a report to TPD would be a reasonable way to get external scientific
expertise. The information from the panel could contribute to information
for the review, but this would not replace external evaluations.
c) Bureau of Gastro-Enterology, Infection and
Viral Diseases (BGIVD)
Abdullah Hassen reported on behalf of Dr. Jacques Bouchard.
The BGIVD has 3 divisions: Gastroenterology, Anti-infective Drugs and
AIDS and Viral Diseases. The challenges include implementation and staffing
of the new structure, introduction of the Common Technical Document
and the use of advisory panels in review.
d) Bureau of Cardiology, Allergy and Neurological
Sciences (BCANS)
BCANS monitors submissions on an ongoing basis with the
intent to divide the workload fairly. The Bureau houses the Central
Nervous System Division, Cardio-Renal Division, Allergy and Respiratory
Drugs Division and Submission Management Unit. Management challenges
are: resourcing, reviewing the use of external reviewers, submission
review performance, backlogs, workflow and linkages. Administrative
challenges of change are somewhat complex in a 5 bureau structure since
certain amount of consistency is desirable. Brigitte Zirger has the
responsibility of coordinating common issues among the 5 bureau managers.
e) Bureau of Pharmaceutical Sciences (BPS)
Sultan Ghani confirmed that the evaluation of the quality
(chemistry and manufacturing) and biopharmaceutics portions of drug
submissions is an integral part of the regulatory process. Key challenges
of BPS are international activities and collaborations (ICH, U.S.P.,
EMEA), streamlining submission process, guidance documents, team building
for generic drugs to meet performance standards and staffing.
f) Bureau of Operational Services (BOS)
Hélène Bélanger described BOS as
a centralization of administrative services and having 5 divisions:
Planning and Management Strategies, Finance and Administration, Information
Management, Submission and Information Policy and Proprietary and Scientific
Information Assessment. The key challenges are defining and clarifying
the roles and responsibilities, work descriptions, staffing, accommodation,
and implementing improved ways of serving clients. The goal is to create
a centre of expertise and excellence in service delivery.
g) Policy Bureau (PB)
Naheed Israeli reported that the objective of the PB
was to develop a model and governance structure for an integrated approach
to policy development in the TPD. The key deliverables are prioritization
of workload, project management system supported by Microsoft Project
and an organization structure which will optimize workflow. Inter Directorate
policy is managed through bilateral meetings and a strategic planning
table at the Branch level.
h) Medical Devices Bureau
Dr. Peterson announced that Beth Pieterson has moved
to Healthy Environments and Consumer Safety Branch. He stated that the
TPD is fortunate in having Roland Rotter as acting Director. The structure
of the MDB has not changed, and they face challenges of responsiveness
and international harmonization.
3.2 Biologics and Genetic Therapies Directorate (BGTD)
After extensive recruitment, a DG for BGTD still has not
been named.
3.3 Marketed Health Products Directorate (MHPD)
Robert Leitch reported for the Chris Turner, the Acting
DG of MHPD. MHPD has broadened the scope of the former Bureau of Licenced
Product Assessment to include natural health products and novel foods,
resulting in its acquiring more resources and Directorate status. MHPD
is interested in continuing to participate with TPD's ACM. The
activities of the MHPD include:
-
monitoring and collecting adverse reaction and medication
incident data
-
reviewing and analyzing marketed health product safety
data
-
conducting risk/benefit assessments of marketed health
products
-
communicating product related risks to health care
professionals and the public
-
overview of regulatory advertising activities
-
active surveillance and product effectiveness projects
Regulatory responsibility for marketed health product
lines will remain with the currently responsible Directorates. A team
approach involving pre- and post-approval regulatory officers will be
used to avoid duplication of efforts and enhance consistency of approach.
National adverse reaction (AR) reporting activities are
coordinated by the Marketed Health Products Directorate of Health Canada.
Voluntary reports are currently collected by five Regional AR Centres
(British Columbia, Saskatchewan, Ontario, Québec and Atlantic)
in addition to the National Office (Ottawa, Ontario). Regional Centres
perform an initial review of the quality and completeness of the reports
which are then processed and further analyzed at the National Office.
An example of a surveillance pilot project is the Mother
Net Pilot Project . It is creating a system that will share information
on the effects of drugs used by pregnant or breast-feeding women on
their fetus or child. The information can then be used to advise women
and health care professionals on the potential side effects or benefits
of starting or continuing to take a given drug during pregnancy or breast
feeding. The MHPD was encouraged to include pharmacists in their such
surveillance pilot projects. Pharmacies could be used to post advisories
that direct people on how to report an AR and alert consumers to references
in the Compendium of Pharmaceuticals and Specialties (CPS).
4. Policy/Regulatory
4.1 Enviro nmental Assessment
Karen Proud, HPFB's project manager for Environmental
Assessment Regulations (EARs), delivered a presentation aimed at providing
the ACM with an understanding of the key issues with respect their potential
impact on pharmaceuticals and medical devices. Under the Food and Drugs
Act (F&DA), Health Canada (HC) is responsible for safety, efficacy
and quality of food, pharmaceuticals and health products. Under the
Canadian Environmental Protection Act, HC shares responsibility for
protection of the environment. In September 2001, HC published a Notice
of Intent in Canada Gazette (CG) Part I to inform Canadians that it
would be developing EARs for substances in products regulated under
the F&DA, to minimize pollutants in the environment. An open dialogue
is ongoing with stakeholders on this initiative. A national science
agenda and education initiatives are being developed and implemented.
International requirements are being compared and a regulatory framework
for consultation is being established. It is HC's intent to have
regulations ready to be published in CG 1 by fall 2003. More information
can be found at their website at www.hc-sc.gc.ca/ear-ree.
4.2 National Placebo Initiative
An executive summary of the National Conference on the
Appropriate Use of Placebos in Clinical Trials (March 22-23, 2002 in
Ottawa) was distributed. P. Huston gave an overview of the progress
to date, plans for 2002-03 and the future challenges. The aim is to
find common ground and consensus building through probing beliefs of
both research ethics and regulatory guidelines. The ACM commended Pat
on her process of objectively looking at evidence and assumptions. More
information can be found at www.cihr-irsc.gc.ca
4.3 Regulator's Role in Biodefense
Dr. Peterson described the regulator's role in biodefence.
Mechanisms in the Food and Drugs Act currently available to the regulator
to approve drugs are clinical trials, Notice of Compliance for new drugs
and the Special Access Programme. These may not be suitable or adequate
to provide access to drugs that would treat, reduce or prevent the toxicity
of chemical, biological, radiological and nuclear substances. Options
are being considered that would enable Health Canada to respond more
quickly and effectively to emergency events. TPD heard comments from
the ACM on the positive nature of this initiative and indicated an interest
in receiving updates as progress is made. These include consideration
of the regulator's role, challenges of meeting public health security
needs in the event of a bioterrorist event and the challenges of considering
drug submissions that do not fit our current Act and regulations.
4.4 Information Management Renewal
A. Butterfield provided the ACM with an overview of the
status of TPD's knowledge management projects and the strategy
for renewal. An action plan will be developed for phasing in of e-review,
guided by an inter-directorate Steering Committee. Needs and gap analysis
relative to the prototype E-SAP and e-CTA applications have been completed,
and the decision taken to discontinue further development. Depending
on the conclusions regarding phasing of e-review, an alternative application
for e-CTA may be developed using standard tools. Priority will also
be given to developing an electronic application to support SAP. A date
for accepting submissions electronically in Common Technical Document
format (eCTD) is not yet defined, but will likely be in July 2003. The
TPD website is undergoing a facelift and updating.
The ACM members commented that they have experienced difficulty
in successfully using Health Canada's search engines. It was proposed
that it is not helpful to put documents in the "what's new"
category if only the name has changed; this should be done when there
is content change.
4.5 TPD Strategic Plan
Mike Ward and Naheed Israeli provided a report on the February 2002
extended management retreat on strategic planning. Themes, priority
areas and linkages were identified and trends and issues were named
within the context of the key drivers.
The ACM participated in an interactive brainstorming session
with the presenters to further define issues:
- Demographics - shift in types of therapeutic products
used; use in smaller populations; targeted use; shorter clinical trials;
larger volume of products submitted; anti-aging bias leads to new
products (Botox for seniors); 100+ years of healthy living; sophistication
in understanding of chronic illnesses which can lead to an increase
in sophistication of self use kits for diagnosis; more patient involvement
in what goes into one's body; complexity of many microtherapies
interacting with each other; smart medical devices that blend science
with IT; blending of biologics and drugs
- Environment - impact of environment on natural immunity
- disinfectants, closed environments lead to increase in allergy and
asthma; need to manage the chemicals we put into environment by targeting;
sensitivity of measurement identifies more environmental contaminants;
impact vs probability as criteria for developing strategy; risk management
strategy important; public expectations and perceptions: feeling vs
being healthy
- Economics: what you can control, who takes on accountability;
globalization issue driven from productivity, innovation, attracting
growth; anti harmonization movement;
- Science and Technology: conditional approval of drugs
- NOC/C could become the norm; smart technology for internet empowers
consumer; disruptive technologies replacing old ways of doing things
in the health care provision environment; product life cycles puts
pressure on regulator and industry
- National and International Governance: challenge
between failing to share sovereignty and the importance of doing so
- Perceptions, Beliefs, Values and Attitudes: changing
demand for risk analysis and communication; major shift in public
perception that all drugs are the same; interaction of health care
processionals with their patients; behaviors should be considered
in this category also - behaviors vs what people think you want to
hear
All agreed that the TPD needs to do short, medium and
long term strategic planning and must build in the flexibility to adopt
plans easily.
DAY2 - May 9, 2002
4.6 Recap of Day 1 and Administration Issues
J. Blackburn will write a letter to the Deputy Minister
of Health thanking him for attending the ACM dinner the previous evening
and his candor.
4.7 Cost Recovery Policy
Andy Butterfield informed the ACM on the status of the
Cost Recovery Initiative 2 (CRI-2) and sought feedback on key questions:
-
if there is agreement in principle to increased fees
to meet performance targets, what conditions should apply?
-
what regulatory activities should be covered?
-
what would be the definition of agreed service levels
and associated costs?
-
what would be the consequences for not meeting service
levels?
-
do stakeholders have concerns with the Drug Establishment
Licencing fee structure sufficient to warrant developing a simplified
approach?
-
how do we make this a dynamic model that meets needs
over time?
-
what are the expectations regarding performance?
The target implementation date for revised drug fee regulations
is October 2003, with medical device fee changes following in April
2004.
The existing Treasury Board "Cost Recovery and Charging
Policy" the draft TB "External Charging Policy" were
compared.
It was noted that the draft policy supports defining an
agreed level of service during consultation on fees. The cost of delivering
this level of service would then be the basis for the proposed fees.
The TPD assume that there would be certain conditions for stakeholder
support for this, including: accountability for performance; costs based
on efficient processes; transparency of costing; and, clear allocation
of revenue to activities for which it was charged.
The HPFB intend to ensure that any fee increase is not linked to further
decreases in appropriation funding.
The current fees are based on costing done between 1994
and 1998 and have not changed, while cost of operations and salaries
have gone up. Revision to bring fees into line with costs is clearly
required. Health Canada will be changing its time tracking of reviews
to ensure an increase in fees has a clear identifiable link to improved
review time. New considerations include an increase in post market activities,
which are now handled elsewhere in the Branch, and cost effectiveness.
ACM comments varied, from complete agreement with the
assumptions TPD have made regarding stakeholder conditions for supporting
larger fees, to agreement with them in principle, but recognition that
financial consequences for not meeting review targets could be problematic.
It was suggested that TPD canvas members via e-mail to obtain further
comments.
4.8 Drug Investigation and Children
Dr. MacLeod reported on the April 26-27 meeting in Ottawa
sponsored by the Canadian Pediatric Society and CIHR. HC and academia
were also in attendance. Communication with the Minister of Health last
fall indicated that drug investigation and children was not a priority.
There is concern regarding the inaction of HC on the question of a regulatory
framework for drug investigation in Canadian children. The Best Pharmaceuticals
for Children Act in the US has modernized approaches in this area. In
Canada, off label use of pharmaceuticals in children makes proactive
studies imperative. Dr. McLeod follow up with writing the appropriate
authorities and identifying a research niche in Canada to bring this
forward.
4.9 Regulation of Natural Health Products
Micheline Ho of SMAB gave presentation on TPD's
responsibilities in the regulation of natural health products (NHP).
It was clarified that the decision to do a detailed risk assessment
on AR reports either in Canada or from other countries depends on the
number of cases and severity of symptoms as determined in MHPD. They
will be also be actively looking at NHP interactions with other drugs.
A disease software scanning capability (Global Public Health Information
Network) exists within HC and this could be modified to include drug
names. Product licence holders are required to report serious ARs to
HC within 15 days.
Philip Waddington presented on the development of regulations
for NHPs. They are guided by advice from consultations and external
advisory committee. Further details can be found on the website at http://www.hc-sc.gc.ca/hpb/onhp/.
Under the Food and Drugs Act, these products will be a subset of drugs.
All NHPs will fall under the Natural Health Products Regulations. Ingredient-based
product monographs are being developed. Claims will be allowed with
a range of Standards of Evidence (SOE) relative to risk of the product
and treatment. The proposed SOE range from traditional references to
clinical trial. This is similar to the current situation within TPD,
where claims for herbs can be made based on traditional or scientific
references. However, the new Regulations should help consumers know
the basis of the information upon which claims are made for these products.
Issues discussed included site licencing, ARs, public
perception, safety, ethnic use of NHPs, risk of replacing other standard
forms of therapy and international harmonization. It was acknowledged
that research into the metabolic processes of drug/NHP interaction is
needed rather than picking this up through ARs. Label warnings for these
potential interactions should accompany both the drug and NHP.
Dr. Blackburn concluded by stating that NHPs are of great
interest to the ACM and they would like to invite Mr. Waddington back
in the future.
5. Tabled Reports
The following reports were tabled for the information
of members. There were no presentations. Members identified that further
discussion was desired on 5.2.
5.1 Product Monograph Project
5.2 Risk Communication
Bill Leslie reported that the report from the Communicating
Drug Safety Information Workshop will be circulated to ACM members once
the participants have approved the draft. He stated that a similar meeting
in Montreal on Risk Communication dealt largely with the same issues.
These were debated by the ACM and are summarized as follows:
- public perception of HC, need to be transparent
- how to get information out
- objective of the message
- audience
- level of trust in the messenger
-
level of knowledge of the messenger
-
public education
-
impact of and relationship with the press
-
definition of risk, public vs professional
-
risk perception differences (gender, ethnic)
-
risk tolerance of new vs old product
-
positioning the message: positive vs negative
-
evaluation of effectiveness of risk communication
It was recommended that HC could start a training program
for science and medical reporting and continue producing fact sheets.
The health professional was recognized as an important link to the patient
and their help should be sought in communications.
5.3 Draft TOR Expert Advisory Panel on Anti-Infectives
5.4 Human Resources Initiative (Final Report)
5.5 Transparency
5.6 Quarterly Report
6. Workplace Health
6.1 TPD Workplace Health Issues Plan
Pauline Gaudry, chair of TPD's Morale and Recognition
Committee, shared information on TPD's recognition process. She
emphasized that the enthusiasm and energy brought about from TPD reorganization
was being harnessed through Committee linkages, volunteering and social
activities.
The ACM commended all on the good progress.
7.0 Next meetings: August 28 & 29,
2002
December 4 & 5, 2002
Meeting adjourned at 2:00 p.m.
Prepared by: Susan Tessier
Date: May 15/02
Revised: June 4/02
|